Plasma national self-sufficiency (sometimes more simply referenced as plasma self sufficiency) refers to a country's ability to meet its own demand for plasma-derived medicinal products (PDMPs) through domestic plasma collection rather than relying on imported raw plasma material for further manufacture or finished PDMPs from other countries such as the United States. Achieving self-sufficiency ensures a stable and secure supply of critical therapies for patients with conditions like immune deficiencies and hemophilia in a given nation. The potential for a plasma derivatives medication shortage most often occurs in countries outside of the United States, as the United States contributes approximately 75% of the world's raw plasma material. A nation's plasma self-sufficiency goal reduces dependency on the United States and international markets, and enhances national healthcare security. Crafting a strategy to meet national self-sufficiency goals is especially important as many nations have learned over the past five years as a result of pandemic, war, geopolitical instability, volatile economies, etc. Governments and organizations, such as the Plasma Protein Therapeutics Association (PPTA), often advocate for national self-sufficiency to improve patient outcomes and support public health initiatives around the globe. Movements such as the Substances of Human Origin (SoHO) legislation in the European Union, is an example of indirect efforts to create national self-sufficiency. Aurea Vita Advisors' (www.AureaVitaAdvisors.com) plasma collection center consultants are able to guide nations through the proper steps to design a strategy and execute tactics in order to reach the overarching objective of become plasma self-sufficient.
Comentarios